NEW YORK (TheStreet) -- TheStreet's Jim Cramer answers Twitter (TWTR) - Get Twitter, Inc. Report questions from the floor of the New York Stock Exchange, and the first one asks where Walmart (WMT) - Get Walmart Inc. Report stands in the wake of Family Dollar's (FDO) deal with Dollar Tree (DLTR) - Get Dollar Tree, Inc. Report.
Cramer calls Dollar Tree a "juggernaut" and tells Walmart to look out. The low end, which used to be Walmart's, is now Dollar Tree's and Cramer loves the store. He finds the prices are great and the selections are terrific and he prefers to go there over Walmart.
The next question asks if suppliers such as GT Advanced Technologies (GTAT) or service providers would benefit when the new iPhone comes out. Cramer responds with Skyworks (SWKS) - Get Skyworks Solutions, Inc. Report and notes Cirrus Logic (CRUS) - Get Cirrus Logic, Inc. Report has come down, but he does not like to out-think these situations. If investors like Apple (AAPL) - Get Apple Inc. Report off an iteration, then they should buy the stock.
Must Watch: Walmart, Family Dollar, Coach Top Cramer's Twitter Q&A
The next question deals with Coach (COH) , which reports earnings after the bell Monday. Cramer calls it "a very troubled institution" and he does not see any relevance there. He thinks there could be a bit of a bounce but says Michael Kors (KORS) led the handbag business, and he has stayed away from this group ever since TheStreet's Herb Greenberg wrote Kors has been slowing. Therefore, he does not want to touch Coach.
In the biotech space, Cramer notes Celgene (CELG) - Get Celgene Corporation Report came down and he thought the quarter was excellent. He says CEO Bog Hugin was not promotional and this is a stock that goes up on announcements of new drugs. He likes this stock, but he also likes Biogen Idec (BIIB) - Get Biogen Inc. Report secondarily because Tecfidera is a maintenance drug that people do not have to take all their lives.
Cramer says Gilead's (GILD) - Get Gilead Sciences, Inc. Report problem is new competition and insurers possibly balking, but he still likes the stock. Finally, Cramer says Regeneron (REGN) - Get Regeneron Pharmaceuticals, Inc. Report must make its anti-cholesterol pill work because Eylea has taken the company as far as it could, but he thinks founder, president and CEO Leonard Schliefer will make it happen.
Lastly, a recent college graduate who has $10,000 in mutual funds and has started a 401k asks Cramer for a stock recommendation, and he does not hesitate to recommend Facebook (FB) - Get Meta Platforms Inc. Class A Report. He thinks the stock will earn $3 in 2016 and could climb to $90 with a 30 multiple.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.